Shots:

• The US FDA has approved Agilent Resolution ctDx FIRST as a liquid biopsy CDx test to identify advanced NSCLC patients with KRAS G12C mutations who may benefit from treatment with Krazati
• Additionally, the test is designed to detect genomic alterations in ctDNA from plasma by using novel propriety technology
• Additionally, ctDx FIRST has also been approved in the US for tumor profiling of the EGFR gene to be used by qualified healthcare professionals for the treatment of NSCLC. Broad genomic profiling on 109 genes, incl. SNVs, insertions, deletions (indels), CNAs, and fusions are included in the ctDX FIRST test report

Ref: Businesswire | Image: Agilent Technologies